Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Cadrenal Therapeutics announced plans to initiate a Phase 3 registration trial for CAD-1005, a first-in-class 12-LOX inhibitor targeting Heparin-Induced Thrombocytopenia (HIT), a severe immune-mediated thrombotic condition. The company will also highlight its broader 12-LOX inhibitor platform addressing inflammatory diseases including diabetes, obe…